Phospholipase C (PLC) enzymes hydrolyse phosphoinositide lipids to inositol phosphates and diacylglycerol. Direct activation of PLCβ by Gαq and/or Gβγ subunits mediates signalling by Gq and some Gi coupled G protein-coupled receptors (GPCRs), respectively. PLCβ isoforms contain a unique C-terminal extension, consisting of proximal and distal C-terminal domains (CTD) separated by a flexible linker. The structure of PLCβ3 bound to Gαq is known, however, for both Gαq and Gβγ, the mechanism for PLCβ activation on membranes is unknown. We examined PLCβ2 dynamics on membranes using hydrogen deuterium exchange mass spectrometry (HDX-MS). Gβγ caused a robust increase in dynamics of the distal C-terminal domain (CTD). Gαq showed decreased deuterium incorporation at the Gαq binding site on PLCβ. In vitro Gβγdependent activation of PLC is inhibited by the distal CTD. The results suggest that disruption of auto-inhibitory interactions with the CTD, respectively, leads to increased PLCβ hydrolase activity.
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of PLCb3 bound to Gaq shows direct interactions of Gaq with the proximal CTD and the EF hands (Waldo et al., 2010) . A more recent structure of full length PLCβ3 includes the extended Cterminus and can serve as a model for the domain organization of all PLCb isoforms ( Fig. 1) (Lyon et al., 2011) . Both the proximal and distal CTD are required for activation by Gaq, however the distal CTD is dispensable for Gβγ activation (Lee et al., 1993; Wu et al., 1993) .
There are two proposed general mechanisms of PLCβ activation, with multiple models proposed for how GPCRs mediate this activation. The binding site for Gαq bound to PLCβ is well defined, but no clear binding site has been identified for Gβγ. Proposed mechanisms of activation involve either the X/Y linker or the proximal CTD (also referred to as the helix loop helix region).
The negatively charged X/Y linker acts as a lid on the active site occluding access to PIP2 substrate.
It has been proposed that negative charges on the flexible region of the linker are repelled upon membrane binding, or reorientation on the membrane surface, and this acts to remove the "lid" allowing for substrate (PIP2) to bind the catalytic site (Hicks et al., 2008) . Genetic deletion of the flexible X/Y linker leads to an increase in basal activity, but this activity can be further stimulated by G-proteins, suggesting there is more to G-protein regulation of PLC activity than removal of the X/Y linker steric occlusion of the active site. A second proposed mechanism for activation involves the proximal CTD being autoinhibitory when packed against the catalytic core of PLC.
In an inactive structure of invertebrate PLC (PLC21) (PDB: 3QR0 and 3QR1) the proximal CTD interacts with the core of the enzyme (Lyon et al., 2013; Lyon et al., 2011) . In Gαq-PLCβ3 cocrystal structures the proximal CTD is pulled away from the core via binding to Gα, leading to disruption of the autoinhibitory interface (Lyon et al., 2011; Waldo et al., 2010) . Supporting this hypothesis, mutations that interfere with the proximal CTD-core interactions cause a robust increase in activity that is not further stimulated by Gαq. 5 There are two proposed binding sites of Gβγ on PLCβ. One of the proposed binding sites for Gβγ on PLCβ is in the PH domain. Indeed, isolated PH domain has been shown to inhibit Gβγ stimulated PLC activity by competing for binding to Gbg and chimeras containing the PH domain of PLCβ2 on PLCδ can confer the ability to be activated by Gβγ subunits (Han et al., 2011; Kadamur and Ross, 2016; Wang et al., 2000) . Interestingly, one proposed PH domain binding site is not surface exposed in structural models of PLC, with binding of Gbg proposed to be mediated by dynamic dissociation from the PLC core, leading to exposure of the Gbg-binding surface on the PH domain (Kadamur and Ross, 2016) . Cross-linking to restrict this putative PH-domain movement inhibits both Gβy binding to, and activation of, PLCβ . The other proposed binding site of Gβγ on PLCβ is in the Y-domain. Mutational analysis of this region decreases Gβγ activation , and peptides corresponding to this region inhibits Gbg-dependent activation of PLCb2, and can be directly crosslinked to Gβγ (Kuang et al., 1996; Sankaran et al., 1998) .
Complicating analysis of the molecular basis for G protein-dependent activation of PLC, is that the activation occurs on a membrane surface, and studying these interactions by standard biophysical methods is extremely challenging.
To further define the molecular mechanisms that mediate activation of PLCb2 by GPCRs on membranes we utilized hydrogen deuterium exchange mass spectrometry (HDX-MS). This technique has provided key insight into the molecular mechanisms of activation of lipid signalling enzymes downstream of GPCRs (Dbouk et al., 2012; Vadas et al., 2013) . Our analysis reveals unique insights into the role of C-terminal domains of PLCb2 in activation by both Gαq and Gβγ.
The results show that Gβγ causes large scale allosteric rearrangement of the distal CTD domain, and that Gaq interacts with the distal CTD as well as the proximal CTD. Biochemical assays reveal a novel direct CTD-catalytic core interaction that inhibits PLC activation. Overall, this work 6 provides fundamental novel insight into unique regulatory mechanisms that control PLCβ activation by GPCRs, and indicates a unifying role for the C-terminal extension in mediating Gprotein activation.
Results:
Activation of PLC by G proteins requires a membrane surface (Charpentier et al., 2014) .
High resolution structural studies of peripheral membrane proteins are generally not compatible with, or are very difficult to perform on membrane surfaces. We used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to examine the dynamics of PLCβ2 in the presence and absence of membranes, Gβγ, and activated Gαq. HDX-MS measures the exchange rate of amide hydrogens with deuterated solvent, and as the main determinant of exchange is the stability of secondary structure, it is an excellent probe of conformational dynamics. Deuterium incorporation is localised at peptide level resolution through the generation of pepsin generated peptides. HDX-MS coverage of PLCβ2 was excellent, with 232 identified peptides that spanned 92% of the primary sequence of PLCβ2. HDX-MS experiments compared the dynamics of PLCb2 on and off lipid vesicles composed of phosphatidylethanolamine(PE), phosphatidylserine (PS), and phosphatidylinositol 4,5 bisphosphate (PIP2), and in the presence or absence of either Gβγ or activated Gαq.
HDX-MS reveals conformational changes in the C-terminus and PLCβ core that occur upon membrane binding
Coincubation of PLCb2 with PS/PE/PIP2 containing lipid vesicles revealed multiple regions of significantly decreased deuterium exchange (defined as changes greater than both 4% 7 and 0.4 Da at any timepoint with a student t-test value less than p<0.05) that occurred across multiple domains of PLCb2 (Figure 2A -C). There were extensive decreases in exchange that occurred on all helices of the distal CTD, spanning regions 878-931, 1020-1109 and 1169-1185. This is consistent with direct interactions of lipid with the distal CTD, which has been shown to be a primary determinant of membrane binding in PLCβ (Adjobo-Hermans et al., 2013; Kim et al., 1996; Wu et al., 1993) . It is possible that some of these changes also may represent conformational changes mediated by interactions of the distal CTD with the PLC core that occur upon membrane binding, since changes were seen on multiple sides of the CTD domain (Lyon et al., 2013) . There were also decreases in exchange in regions spanning the PLCb2 core, including in the EF hand domain (residues 255-290) and C2 domain (694-701). These changes were surprising since these regions would not be predicted to participate in membrane binding based on previous crystallographic studies. Intriguingly, both of these regions are very close to the Cterminus of the C2 domain, which is immediately followed by the proximal CTD domain ( Figure   1 , Figure 2A ). This suggests that these regions are involved in allosteric changes in PLC associated with membrane binding. The region in the C2 domain with decreases in exchange would be predicted to be directly in contact with the putative autoinhibitory proximal CTD binding site based on the PLC21 structure (Lyon et al., 2011) , suggesting a possible change in the interaction of the proximal CTD with the catalytic core upon membrane binding.
We saw no changes in deuterium exchange consistent with the X/Y linker displacement by the membrane surface, but exchange rates in this area were extremely rapid indicating a high degree of flexibility of this region of the protein. We observed decreased deuterium incorporation in the proximal CTD and its linker to the C2 domain of PLCβ2 (residues 813-822).
This may reflect an altered conformation of this region upon binding to membrane or direct 8 interaction with membranes. The helix-loop-helix proximal CTD directly interacts with Gaq, and it is possible that this altered conformation may prime the proximal CTD for interaction with Gaq.
Conformational changes that result from Gαq binding to PLCβ on membranes
Next, we compared HDX rate differences between PLC-liposome complexes to PLC-Gαq-liposome complexes. There were extensive decreases in exchange at regions that correspond directly to the known binding site of Gαq on PLC as determined by X-ray crystallography (Lyon et al., 2013; Lyon et al., 2011) , strongly supporting the validity of this method and our approach.
This included the proximal CTD, which is the principle binding site for Gαq (Lyon et al., 2013; Waldo et al., 2010) showing a >40% decrease in deuterium incorporation ( Figure 3A -D). In addition, regions of the EF hand (residues 255-272), and C2 domain (675-681, 740-745, and 802-812) , either at the interface with Gαq, or directly adjacent, also showed significant decreases in exchange upon binding to Gαq on membranes. This region of the EF hand directly corresponds to structural elements directly involved activation of the GTPase activity of Gaq (Waldo et al., 2010) . There was also an increase in exchange in a region of the EF hands (271-290) adjacent to the Gαq binding interface, revealing allosteric conformational changes that occur upon Gαq binding. The distal CTD showed decreases in exchange directly at the contact site with the Gαq N-terminal region (CTD region 1070-1109), as well as other regions directly adjacent (878-889 and 1020-1029). Gaq appears to contact the N-terminal helix in the Gαq-full length PLCβ3 cocrystal structure but there was some concern that this may represent a crystal packing artefact (Lyon et al., 2013) . The results from the HDX experiments confirm that in solution, in the presence of membranes, many of the contacts seen in the X-ray crystal structures are valid 9 contact sites. Additional conformational alterations are revealed that may be critical for activation.
Gβγ binding to PLCβ on membranes reveals extensive conformational changes in the distal CTD
Next, we compared changes in deuterium incorporation between PLC-membrane complexes and PLC-Gβγ-membrane complexes. The most striking and unexpected effect of Gβγ binding to PLCβ was increased deuterium exchange on almost the entire distal CTD of PLCβ2 (multiple peptides spanning 892-1114) ( Figure 4A -D). This is not due to competition for membrane binding because the other membrane associated changes in dynamics i.e. EF hand and C2 domain do not show this increase. ( Figure 4A -D). Additionally, even under the high protein concentrations used for HDX experiments, Gβγ still increased PLC activity 3-4-fold (Supplemental figure 1 ). This indicates that Gβγ causes PLCβ2 to undergo a conformational change that rearranges the distal CTD. One possibility is that Gβγ binding leads to disruption of an auto-inhibitory interaction of the CTD with the PLCβ2 core. No changes were seen in the PLCβ2 core that would be consistent with this model. However; disruption of intramolecular interactions of the CTD with the core, with concomitant binding of Gβγ to the core would result in no net change in deuterium incorporation in the core.
The distal CTD is autoinhibitory
To test the hypothesis that the distal CTD was autoinhibitory, we generated a PLCβ2 mutation deleting the distal CTD (PLCb2-DCTD). A diagram of this truncation is shown in Figure 5A . We then examined the ability of PLCb2-DCTD to be activated by Gβγ. We incubated varying concentrations of Gβγ with PLCb2-DCTD or full-length PLCb2 in a PLC enzyme activity assay using phospholipid vesicles containing PIP2 substrate. We predicted that the distal CTD-deleted PLC would have increased responsiveness to Gβγ stimulation as it would lack one of the autoinhibitory constraints opposing activation by Gβγ. Gβγ activated PLCb2-DCTD with increased efficacy but no change in the EC50 ( Figure 5B ). Basal Ca 2+ stimulated activity of PLCb2-DCTD was similar to that of full-length PLCβ2 (supplemental figure 2).
These data suggest that the distal CTD may act an autoinhibitory domain.
To provide further evidence that the distal CTD is autoinhibitory, we tested whether the addition of purified distal CTD could inhibit Gβγ stimulated PLCβ activity when incubated with PLCb2-DCTD in trans. We expressed and purified the triple helical bundle of the distal CTD (residues 864-1184) and incubated varying concentrations of purified CTD with Gβγ and PLCb2-DCTD and measured PLC enzyme activity. We predicted that the distal CTD would inhibit Gβγ-dependent PLC activation. The purified CTD inhibited Gβγ stimulated activity with an IC50 of 194 ±46 nM while having no appreciable effect on basal activity ( Figure 5C and D).
One possible explanation of these results is that, since the CTD binds lipids, the CTD added in trans could compete for binding of PLC to the vesicle surface and thereby inhibit PLC activity. The observation that CTD addition did not affect PLC basal activity argues against this hypothesis, but to further test this idea, we measured binding of purified PLCb2 binding to lipid vesicles, in the presence or absence of purified CTD, using a centrifugation-based lipid binding assay. At the highest concentration of CTD tested in the PLC activity reconstitution assay, the CTD had no significant effect on lipid binding of PLCb2-DCTD (Figure5 E, F).
In order to determine if the CTD of PLC directly interacts with the catalytic core of PLCβ, we used biolayer interferometry (BLI) to examine direct binding. We immobilized the CTD of PLCβ2 and examined binding to increasing concentrations of purified PLCb2-DCTD.
PLCb2-DCTD bound directly to the CTD of PLCβ2 with a Kd of 146±88 nM. The response reached equilibrium and exhibited little non-specific binding to the reference tip indicating this is a specific interaction ( Figure 5F , G). Taken together, these data suggest the CTD is inhibitory to PLC activity, and this inhibition is through direct binding of the distal CTD to the catalytic core of PLCβ2
CTD movement is important for activation of PLCβ
To determine if the movement of the distal CTD upon Gβγ binding observed by HDX-MS is important for activation we generated a construct lacking the flexible linker between the proximal CTD and distal CTD (PLCb2-D-linker) ( Figure 6A ). We hypothesized that deleting this linker would prevent the distal CTD from forming auto-inhibitory interactions with the catalytic core due to decreased conformational flexibility ( Figure 6B ). If movement of the distal CTD was important for activation, it would be expected that PLCb2-D-linker would have increased basal activity, and would not be further activated by Gβγ. We examined activation of PLCb2-D-linker by G-proteins in a cos-7 cell co-transfection assay. As expected, PLCb2-D-linker had increased basal activity that was not increased in the presence of either Gβγ or Gαq ( Figure 6C ). Since no further increase was seen in activity in the presence of either G-protein, this suggests a unified mechanism where the orientation of the proximal and distal CTD domains is critical for PLCb2 activation by heterotrimeric G proteins. These data also agree with the changes in dynamics we see in HDX with Gβγ suggesting that the rearrangement of the distal CTD is an integral step in Gβγ activation.
Proximal CTD inhibits PLC activation
As the mechanism of activation of PLCβ by Gαq has been established to use both the distal and proximal CTD, and these two domains are covalently tethered, we hypothesized that distal CTD rearrangement could destabilize the proximal CTD, preventing it from adopting an autoinhibited state. We tested PLCb2 with a c-terminal deletion of both the proximal CTD and distal CTD (PLCb2-D818) and a mutation (PLCb2-P819A) predicted to disrupt formation of the helix loop helix conformation of the proximal CTD that is stabilized upon Gαq binding ( Figure   7A ). Both of these mutations greatly reduced basal PLC activity, but also prevented activation by Gαq, and, surprisingly, Rac1, seen as a significant reduction in the stimulated activity relative to basal activity when Gaq and Rac1 are cotransfected. (Figure 7B , C). This indicates this region is important for activation of PLCb2 by these G proteins. While the Gbg-stimulated activity was reduced (probably as a result of the overall reduction in the PLC activity of these mutants), there was little effect on the ability of Gbg to increase PLC activity relative to the basal activity of that mutant. This suggests less reliance on proximal CTD interactions with the core for the mechanism for activation by Gbg.
Discussion:
Here we used HDX-MS to examine the molecular mechanisms that mediate PLCb3 activation by GPCR subunits Gαq/Gβγ on membranes. Intriguingly, we find that Gβγ binding causes dramatic conformational rearrangement of the distal CTD, suggesting that the CTD is involved in activation by Gβγ. To provide support for this idea we show 1) that the CTD can bind directly to the catalytic core in-trans to inhibit PLC activity, and 2) restricting interactions 13 of the CTD with the catalytic core through removal of the flexible linker strongly increased PLCβ activity that was not further activated by G proteins. Others have shown that deleting the linker of PLCβ3 increases basal activity and this construct cannot be further activated by Gαq (Lyon et al., 2013) , but here we demonstrate that PLCb2 with the CTD-linker deleted did not respond to either heterotrimeric G-protein, suggesting that movement of the distal CTD is important for activation by both G-proteins.
Deletion or mutation of the proximal CTD did not dramatically inhibit Gβγ-dependent activation of PLC, suggesting that rearrangement of the proximal CTD is not required for Gbg activation. These data indicate that rearrangement of either the proximal or distal CTDs are generally involved in all activation processes, while proximal CTD rearrangement is critical for regulation of activity Gαq and Rac but not Gbg.
It is interesting to note incubation with phospholipid vesicles caused decreased deuterium exchange in several domains not thought to be involved in membrane binding. Domains far from the active site and the C-terminus that show decreased dynamics on lipid vesicles include the EF hands and the proximal CTD. This suggests that there are conformational changes in PLC that occur upon membrane binding, and this might be due to either changed inter-domain interfaces or conformational changes in PLC upon membrane binding. Since membranes are critical for the allosteric activation of PLCβ enzymes by G-proteins, these conformational changes could be essential for activation by Gβγ or Ga, as predicted for G-protein activation of class I PI3Ks (Dbouk et al., 2012; Vadas et al., 2013) . It has been shown that conformational flexibility involving EF hands 3 and 4, and the PH domain are important for activity of multiple PLC variants (Garland-Kuntz et al., 2018) . Surprisingly, we did not observe G-protein or membrane dependent changes in deuterium exchange in either the X/Y linker, PH domain, or the Y domain. There were no changes in the dynamics of the interface between the PH domain and EF hand in the presence of membranes or G proteins. Overall our data does not provide evidence to support rearrangement of the X/Y linker by the membrane, a dynamic PH-EF hand interface for Gbg binding, or binding of Gbg to the Y domain, but the HDX-MS data are not incompatible with these processes.
A surprise from our data is that activation of PLCb by different G-proteins converge on a unifying mechanism involving disruption of inhibition by the c-terminal extension, with the different proximal and distal CTD domains participating in different ways. On membrane surfaces, Gαq interfaces directly with the proximal CTD and distal CTD, with these interactions disrupting all auto-inhibitory interactions. On membranes Gβγ disrupts auto-inhibition by the distal CTD, most likely due to it forming a direct interface with a portion of the PLCβ core. The direct interface of the Gβγ interface with the PLC core is unknown. It is unclear why no regions were protected from exchange by Gbg binding. It is possible that the region exposed upon disruption of the distal CTD domain inhibitory interface is what is responsible for Gβγ binding, and this would lead to no overall difference in deuterium incorporation.
Our data, taken together, suggest an activation mechanism of PLC by Gβγ where Gβγ causes a conformational rearrangement of the distal CTD through an allosteric mechanism, breaking the interaction between the catalytic core and the distal CTD, while Gαq binds directly to both the proximal and distal CTD in order to break autoinhibitory interactions of the Cterminal domain, in this way activation of PLCβ by either G-protein involves C-terminal domain rearrangement but each G-protein engages this regulatory region of PLC differently, Gαq utilizing direct interaction while Gβγ somehow coordinates a conformational change involving 15 this region. (Figure 8 ). Further study will be required to conclusively define the exact molecular mechanisms by which Gβγ both directly binds to PLCβ, and releases auto-inhibition.
Methods:

Transfection of COS-7 cells and quantitation of phospholipase C activity
All cell culture reagents were obtained from Invitrogen. COS-7 cells were obtained from ATCC. COS-7 cells were seeded in 12-well culture dishes at a density of 100,000 cells per well and maintained in high-glucose Dulbecco's modified Eagle's medium containing 5% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37 °C. The following day 
Purification of Gβγ and Gαq
Purification of Gβ1γ2 (Gβγ) was performed by co-expressing Gβγ with His6 Gαi1 in High Five insect cells and nickel-agarose chromatography as described previously (Davis et al., 2005; Kozasa and Gilman, 1995) . Purification of Gα was performed as described in (Kozasa and Gilman, 1995) .
Purification of His6 PLCβ2, PLCβ2-Δ856, PLCβ2 C-terminal domain.
Baculovirus-infected Sf9 cells expressing PLCβ2 and PLCβ2-Δ856, or the C-terminal domain of PLCβ2 were lysed by Dounce on ice in lysis buffer containing 20 mM HEPES, pH 8, 50 mM NaCl, 10 mM β-mercaptoethanol, 0.1 mM EDTA, 0.1 M EGTA, 133 µM PMSF, 21 µg/ml TLCK and TPCK, 0.5 µg/ml Aprotonin, 0.2 µg/ml Leupeptin, 1 µg/ml Pepstatin A, 42 µg/ml TAME, 10 µg/ml SBTI. The lysate was centrifuged at 100,000 × g, and the supernatant was collected and diluted with lysis buffer with NaCl to a final concentration of 800 mM. The diluted supernatant was then centrifuged at 100,000 x g and the supernatant was loaded onto a Ni-NTA column pre-equilibrated with buffer A (20 mM HEPES, pH 8, 100 mM NaCl, 10 mM β-mercaptoethanol, 0.1 mM EDTA, and 0.1 M EGTA). The column was washed with 3 column volumes (CVs) of buffer A, followed by 3 CVs of buffer A supplemented with 300 mM NaCl and 10 mM imidazole. The protein was eluted from the column with 3-10 CVs of buffer A, 
Biolayer interferometry (BLI)
Protein-Protein interactions were measured by biolayer interferometry using an 8 channel Octet
Red system (ForteBio). A 1.5-2 nm shift of PLCβ2-CTD was immobilized on AR2G biosensor tips (Fortebio) by activation with EDC-NHS solution freshly prepared according to manufacturer's instructions. PLCβ2-Δ856 binding to the immobilized protein was measured at the specified final protein concentrations in buffer containing 20 mM HEPES pH8, 100 mM NaCl, 0.1% BSA and 0.02% Tween, at room temperature and with vigorous shaking (2,200 rpm). Assays were performed at least in triplicate, and binding isotherms were constructed by representing the experimental binding values at equilibrium versus the CTD total concentration.
Hydrogen deuterium exchange mass spectrometry (HDX-MS)
HDX experiments were performed with or without liposomes (final concentration 0.1 mg/mL) containing brain porcine phosphatidylethanolamine, brain porcine phosphatidylserine and brain porcine phosphatidylinositol 4,5-bisphosphate in a 10:5:1 molar ratio (Avanti Polar Lipids) in a total reaction volume of 50 µl with a final concentration of 400 nM PLC, 1mM NaF, 30µM
AlCl3 and 600 nM Gαq or Gβγ where appropriate. Deuterium incorporation was initiated by the addition of 40 µl of deuterium oxide buffer (75 mM HEPES pH 7.5, 50 mM NaCl, and 69%
(v/v) final deuterium oxide). The constructs were allowed to exchange over three time courses: 3, 30, 300, and 3000s at 16 °C. Exchange was terminated by the addition of 25 µl of ice-cold quench buffer (3% formic acid, 2M guanidine), and samples were immediately frozen in liquid nitrogen.
MS experiments were carried out as described previously (Vadas et al., 2017) . In brief, samples were quickly thawed and injected onto an ultra-performance LC system (Dionex Ultimate 3000
RSLCnano system coupled to a leap technologies PAL RTC) at 2 °C. The samples were subjected to two immobilized pepsin columns (Applied Biosystems, Poroszyme, 2-3131-00) at 10 and 2 °C, respectively, at a flow of 200 µl/min for 3 min. Peptides were subsequently collected and desalted on a VanGuard precolumn Trap column (Waters) and were eluted onto an Acquity 1.7 µM particle, 100 × 1 mm2 C18 ultra-performance LC column (Waters). Separation and elution of peptides from the analytical column was achieved using a gradient ranging from 3 to 70% mobile phase B (buffer A: 0.1% formic acid, LC/MS grade; buffer B: 100% acetonitrile, LC/MS grade) over 16 min. Mass spectrometry analyses were performed using an Impact II TOF (Bruker) with an electrospray ionization source operated at a temperature of 200 °C and a spray voltage of 4.5 kV, and data were acquired over a range of 150-2200 m/z. Peptides were identified using the software program PEAKS 7. The false discovery rate was set to 1%.
Levels of deuterium incorporation were calculated using the HD-Examiner Software (Sierra Analytics), and data from each individual peptide were inspected for correct charge state, quality of spectra, and the presence of overlapping peptides. Levels of deuteration were computed by HD-Examiner using the centroid of the isotopic cluster corresponding to each peptide at each time point. The deuteration levels calculated are presented as relative levels of deuterium incorporation, the data were further analyzed and curated using Excel, and changes in deuteration levels above 4% and 0.4 Da with a paired t test value of p < 0.05 were deemed to be significant. All deuterium incorporation values for all peptides can be found in the xls file in the source data. The full analysis parameters as required by the IC-HDX-MS (Masson et al., 2019) for all experiments are found in supplemental table 1. resuspended pellet was denatured with 4 µl of 5× SDS loading dye, and 10 µL of the total sample was analyzed by SDS-PAGE using anti-PLCβ2 antibody (Invitrogen Ca#PA5-75551).
Phospholipase C activity assay
The assay was performed as described previously , with minor modification. Briefly, lipids containing ∼5000 cpm of [3H-inositol]PIP2, 37.5 µM PIP2, and 150 µM phosphatidylethanolamine were mixed with 1.4 ng of FL PLCβ2 and equimolar amounts of Δ856-PLCβ2 (1 ng). Varying concentrations of Gβγ were added to the PLC and lipid mixture.
The reaction was set at 30 °C for 30 min in the presence of 1.5 mM CaCl2 and 3 mM EGTA (Free Ca 2+ =100nM), and quenched using ice cold 10% TCA. Released soluble [ 3 H] IP3 was separated through the addition of 5% BSA and centrifugation then measured by liquid scintillation counting. Basal activity is defined as the activity in the presence of Ca 2+ and no other protein activators.
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